Keith Regnante is the Chief Financial Officer of City Therapeutics. He is a seasoned CFO with more than 25 years of public biopharmaceutical company finance experience. Prior to joining City, Mr. Regnante served as CFO of Keros Therapeutics, where he led the company’s finance organization during a time of significant growth and capital financing, including an IPO, two follow-on offerings and a global licensing agreement with Takeda Pharmaceuticals.

Previously, Mr. Regnante served as CFO of Wave Life Sciences. Earlier in his career, he held finance leadership roles of increasing responsibility at Shire Pharmaceuticals and Biogen, including senior positions in corporate finance and global research and development finance, as well as roles in investor relations and business development finance. At Biogen, he contributed to major transactions including the company's acquisition of Elan Pharmaceuticals' rights to Tysabri and its merger with IDEC Pharmaceuticals. He began his career as a consultant at the Boston Consulting Group and KPMG. Mr. Regnante earned an MBA from the MIT Sloan School of Management and a bachelor’s degree in economics from Tufts University.